13F 申報指南13F 觀念全攻略
什麼是 SEC Form 13F 申報？美股機構大戶持股全攻略
完整解讀 Form 13F 申報規範、1 億美元門檻與 45 天延遲申報機制，學會如何追蹤頂級對沖基金與機構法人持倉動向。
AlphaSMO 權威研究指南閱讀專題
CIK: 0001617201
申報總市值
US$5.8億
US$5.8億
36 檔
22.6%
Prosight Management, LP 在 Q4 2024 季度的美股部位總計估值為 US$5.8億，分散於 36 個持倉標的之中，反映其市場參與廣度與投資規模。
數據顯示 Prosight Management, LP 於 Q4 2024 季度持續回收資金，對 15 個既有部位進行裁減並清倉 17 個標的，組合整體流動性比重有所上升。
在資產配置集中度方面，Prosight Management, LP 的前 5 大核心持股（包含 LKFT, ACHC, BBIO 等）合計佔整體申報市值的 22.6%，反映機構在主要關鍵部位上的權重分佈。
| # | 代號 | 標的名稱 | 資產子類別 | 佔比 | 佔比變動 | 持倉量變化 | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | LKFT | Lakefront Biotherapeutic-adr | 股票-其他 | 7.79% | +2.93% | -0.37% | |
| 2 | ACHC | Acadia Healthcare Co Inc | 股票-其他 | 7.58% | — | +12113.20% | |
| 3 | BBIO | Bridgebio Pharma Inc | 股票-醫療保健 | 7.55% | — | -8.45% | |
| 4 | MGTX | MeiraGTx Holdings plc | 股票-其他 | 7.39% | -3.52% | -10.40% | |
| 5 | ABCL | Abcellera Biologics Inc | 股票-其他 | 5.95% | — | -19.05% | |
| 6 | ✓ | Adc Therapeutics SA | 股票-其他 | 5.23% | -3.66% | -1.26% | |
| 7 | MIRM | Mirum Pharmaceuticals Inc | 股票-其他 | 5.16% | — | -3.16% | |
| 8 | ICLR | ICON Public Limited Company | 股票-醫療保健 | 4.93% | — | — | |
| 9 | ROIV | Roivant Sciences Ltd. | 股票-醫療保健 | 4.90% | -0.82% | EXIT | |
| 10 | JANX | Janux Therapeutics Inc | 股票-其他 | 4.88% | +1.98% | +60.86% | |
| 11 | SDGR | Schrodinger Inc | 股票-其他 | 3.84% | -0.95% | EXIT | |
| 12 | RCKT | Rocket Pharmaceuticals Inc | 股票-其他 | 3.78% | +0.01% | +583.14% | |
| 13 | ZYME | Zymeworks Inc | 股票-其他 | 3.32% | +0.83% | -10.64% | |
| 14 | KURA | Kura Oncology Inc | 股票-其他 | 3.19% | -0.66% | +87.91% | |
| 15 | AM6 | Amicus Therapeutics Inc | 股票-其他 | 2.40% | — | — | |
| 16 | ZBH | Zimmer Biomet Holdings Inc | 股票-醫療保健 | 2.34% | — | -51.69% | |
| 17 | SNDX | Syndax Pharmaceuticals Inc | 股票-其他 | 2.27% | +1.57% | +11.89% | |
| 18 | STTK | Shattuck Labs Inc | 股票-其他 | 2.22% | +1.84% | +16.91% | |
| 19 | IMVT | Immunovant Inc | 股票-其他 | 2.09% | -0.72% | EXIT | |
| 20 | 2655787D | Blueprint Medicines CORP | 股票-其他 | 1.62% | — | +42.25% | |
| 21 | PRTA | Prothena Corporation plc | 股票-其他 | 1.60% | — | -13.52% | |
| 22 | ✓ | Galapagos NV | 股票-其他 | 1.34% | — | — | |
| 23 | CTMX | Cytomx Therapeutics Inc | 股票-其他 | 1.11% | — | +29.21% | |
| 24 | HAE | Haemonetics Corp/mass | 股票-其他 | 1.01% | — | -28.15% | |
| 25 | CNC | Centene CORP | 股票-醫療保健 | 0.92% | — | — | |
| 26 | SGHT | Sight Sciences Inc | 股票-其他 | 0.91% | — | +71.09% | |
| 27 | LIVN | LivaNova PLC | 股票-其他 | 0.90% | — | -22.22% | |
| 28 | CRBP | Corbus Pharmaceuticals Holdi | 股票-其他 | 0.88% | -0.02% | +107.69% | |
| 29 | ERAS | Erasca Inc | 股票-其他 | 0.66% | — | -52.26% | |
| 30 | SYRE | Spyre Therapeutics Inc | 股票-其他 | 0.51% | — | — | |
| 31 | CDNA | Caredx Inc | 股票-其他 | 0.47% | — | — | |
| 32 | ✓ | Mural Oncology Pub LTD Co | 股票-其他 | 0.42% | — | -18.19% | |
| 33 | FTRE | Fortrea Holdings Inc | 股票-醫療保健 | 0.28% | — | — | |
| 34 | RNTX | Rein Therapeutics Inc | 股票-其他 | 0.26% | +0.11% | +8.82% | |
| 35 | IMNM | Immunome Inc | 股票-其他 | 0.16% | — | +38.86% | |
| 36 | OKUR | Onkure Therapeutics Inc-a | 股票-其他 | 0.15% | -0.69% | — |
| # | 代號 | 標的名稱 | 佔比變動 | 持倉量變化 | 異動類型 |
|---|---|---|---|---|---|
| 1 | ACHC | Acadia Healthcare Co Inc | +7.5% | +12113.20% | 加碼 |
| 2 | ICLR | ICON Public Limited Company | +4.9% | NEW | 新建倉 |
| 3 | RCKT | Rocket Pharmaceuticals Inc | +3.1% | +583.14% | 加碼 |
| 4 | JANX | Janux Therapeutics Inc | +2.6% | +60.86% | 加碼 |
| 5 | AM6 | Amicus Therapeutics Inc | +2.4% | NEW | 新建倉 |
| 6 | MGTX | MeiraGTx Holdings plc | +2.4% | -10.40% | 減碼 |
| 7 | ✓ | Galapagos NV | +1.3% | NEW | 新建倉 |
| 8 | CNC | Centene CORP | +0.9% | NEW | 新建倉 |
| 9 | BBIO | Bridgebio Pharma Inc | +0.7% | -8.45% | 減碼 |
| 10 | MIRM | Mirum Pharmaceuticals Inc | +0.7% | -3.16% | 減碼 |
| 11 | SDGR | Schrodinger Inc | +0.6% | +2.93% | 加碼 |
| 12 | 2655787D | Blueprint Medicines CORP | +0.6% | +42.25% | 加碼 |
| 13 | SYRE | Spyre Therapeutics Inc | +0.5% | NEW | 新建倉 |
| 14 | LKFT | Lakefront Biotherapeutic-adr | +0.5% | -0.37% | 減碼 |
| 15 | ZYME | Zymeworks Inc | +0.5% | -10.64% | 減碼 |
| 16 | CDNA | Caredx Inc | +0.5% | NEW | 新建倉 |
| 17 | FTRE | Fortrea Holdings Inc | +0.3% | NEW | 新建倉 |
| 18 | CTMX | Cytomx Therapeutics Inc | +0.2% | +29.21% | 加碼 |
| 19 | CRBP | Corbus Pharmaceuticals Holdi | +0.2% | +107.69% | 加碼 |
| 20 | OKUR | Onkure Therapeutics Inc-a | +0.2% | NEW | 新建倉 |
| 21 | ABCL | Abcellera Biologics Inc | +0.1% | -19.05% | 減碼 |
| 22 | SGHT | Sight Sciences Inc | +0.1% | +71.09% | 加碼 |
| 23 | IMNM | Immunome Inc | 0% | +38.86% | 加碼 |
| 24 | ROIV | Roivant Sciences Ltd. | 0% | -12.87% | 減碼 |
| 25 | ✓ | Mural Oncology Pub LTD Co | 0% | -18.19% | 減碼 |
| 26 | RNTX | Rein Therapeutics Inc | -0.1% | +8.82% | 加碼 |
| 27 | ✓ | Shattuck Labs Inc | -0.1% | EXIT | 清倉 |
| 28 | IMRX | Immuneering CORP - Class A | -0.1% | EXIT | 清倉 |
| 29 | KURA | Kura Oncology Inc | -0.2% | +87.91% | 加碼 |
| 30 | OVID | Ovid Therapeutics Inc | -0.2% | EXIT | 清倉 |
| 31 | SEM | Select Medical Holdings CORP | -0.2% | EXIT | 清倉 |
| 32 | ✓ | Corvel CORP | -0.2% | EXIT | 清倉 |
| 33 | LIVN | LivaNova PLC | -0.3% | -22.22% | 減碼 |
| 34 | HAE | Haemonetics Corp/mass | -0.3% | -28.15% | 減碼 |
| 35 | SNDX | Syndax Pharmaceuticals Inc | -0.4% | +11.89% | 加碼 |
| 36 | PRTA | Prothena Corporation plc | -0.4% | -13.52% | 減碼 |
| 37 | ✓ | Vincerx Pharma Inc | -0.4% | EXIT | 清倉 |
| 38 | MRVI | Maravai Lifesciences Hldgs-a | -0.4% | EXIT | 清倉 |
| 39 | IMVT | Immunovant Inc | -0.5% | -17.43% | 減碼 |
| 40 | ERAS | Erasca Inc | -0.7% | -52.26% | 減碼 |
| 41 | VKTX | Viking Therapeutics Inc | -0.8% | EXIT | 清倉 |
| 42 | TECX | Tectonic Therapeutic Inc | -1% | EXIT | 清倉 |
| 43 | ✓ | Cassava Sciences Inc | -1.1% | EXIT | 清倉 |
| 44 | COGT | Cogent Biosciences Inc | -1.1% | EXIT | 清倉 |
| 45 | ✓ | Ishares Tr | -1.6% | EXIT | 清倉 |
| 46 | NBIX | Neurocrine Biosciences Inc | -1.8% | EXIT | 清倉 |
| 47 | ZBH | Zimmer Biomet Holdings Inc | -2.1% | -51.69% | 減碼 |
| 48 | ✓ | Adc Therapeutics SA | -2.2% | -1.26% | 減碼 |
| 49 | CYTK | Cytokinetics Inc | -2.5% | EXIT | 清倉 |
| 50 | DXCM | Dexcom Inc | -2.6% | EXIT | 清倉 |
根據 SEC 官方 Form 13F 申報備案，Prosight Management, LP 在 Q4 2024 季度的美股持倉總市值約為 US$5.8億，共申報了 36 個公開持股部位。
在 Q4 2024 季度，Prosight Management, LP 按市值排列的前三大核心持股分別為：LKFT (7.8%)、ACHC (7.6%)、BBIO (7.5%)。其中最大持股部位 LKFT 佔據整體投資組合約 7.8% 的權重。
精選 AlphaSMO 大戶持股與內部人交易深度分析，提升投資決策勝率
完整解讀 Form 13F 申報規範、1 億美元門檻與 45 天延遲申報機制，學會如何追蹤頂級對沖基金與機構法人持倉動向。
本季最大新建倉標的
ICLR
市值: US$1782.5萬
本季最大獲利了結 / 清倉標的
MCK
前期市值: US$1771.1萬
在 Q4 2024 季度中，Prosight Management, LP 共進行了 53 項持倉異動，包含新建倉 8 個部位、加碼 13 個部位、減碼 15 個部位以及清倉 17 個部位。 其中最大新建倉標的為 ICLR。 本季清倉部位包含 MCK。
本頁面所有持股數據均直接同步自美國證券交易委員會（SEC）EDGAR 官方系統之 13F-HR / 13F-HR/A 季度申報文件。AlphaSMO 透過機器解析 CUSIP 與個股對照，提供 100% 精準對齊的歷史時序數據集，並支援 Schema.org 結構化資料格式。
解析公司高管、董事與 10% 大股東之 Form 4 內部人交易申報，掌握高管自家股票買賣第一手訊號。
深入剖析 5% 股益申報門檻、13D 與 13G 之差異，以及最新 SEC 申報時程規範，洞察機構法人的激進投資動向。